UY38405A - Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos - Google Patents
Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismosInfo
- Publication number
- UY38405A UY38405A UY0001038405A UY38405A UY38405A UY 38405 A UY38405 A UY 38405A UY 0001038405 A UY0001038405 A UY 0001038405A UY 38405 A UY38405 A UY 38405A UY 38405 A UY38405 A UY 38405A
- Authority
- UY
- Uruguay
- Prior art keywords
- zolpidem
- pharmaceutically acceptable
- solutions
- formulations
- acceptable salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001475 zolpidem Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000035515 penetration Effects 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención trata de soluciones oromucosas de Zolpidem o sales farmacéuticamente aceptables del mismo. La presente invención se refiere a formulaciones bucales o sublinguales de Zolpidem o una sal farmacéuticamente aceptable del mismo. Las formulaciones minimizan la cantidad de potenciadores de la penetración y, sin embargo, proporcionan una rápida penetración transmucosal del fármaco. Estas formulaciones no solo proporcionan la concentración deseada (0.5% a 10% p/v ) del medicamento en forma de solución transparente (clara), sino que también logran formulaciones estables durante toda la vida útil de al menos aproximadamente 2 años. El pH de las soluciones estables no acuosas de la presente invención está en el intervalo de pH 5 a 9, preferiblemente de 6 a 9, más preferiblemente de 7 a 9.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821038060 | 2018-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38405A true UY38405A (es) | 2020-03-31 |
Family
ID=68296607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038405A UY38405A (es) | 2018-10-08 | 2019-10-07 | Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US12133845B2 (es) |
| EP (1) | EP3863604B1 (es) |
| JP (1) | JP2022501407A (es) |
| KR (1) | KR102860999B1 (es) |
| CN (1) | CN112996488B (es) |
| AR (1) | AR116721A1 (es) |
| AU (1) | AU2019358394B2 (es) |
| BR (1) | BR112021006551A2 (es) |
| CA (1) | CA3115195A1 (es) |
| CL (1) | CL2021000856A1 (es) |
| CO (1) | CO2021005969A2 (es) |
| DO (1) | DOP2021000060A (es) |
| EA (1) | EA202190765A1 (es) |
| EC (1) | ECSP21024213A (es) |
| ES (1) | ES2998438T3 (es) |
| GE (1) | GEP20237492B (es) |
| HU (1) | HUE069302T2 (es) |
| IL (1) | IL282020B2 (es) |
| JO (1) | JOP20210068A1 (es) |
| MA (1) | MA53050B1 (es) |
| MX (1) | MX2021003975A (es) |
| PE (1) | PE20211007A1 (es) |
| PH (1) | PH12021550748A1 (es) |
| PL (1) | PL3863604T3 (es) |
| SG (1) | SG11202103255RA (es) |
| TN (1) | TN2021000051A1 (es) |
| UY (1) | UY38405A (es) |
| WO (1) | WO2020075183A1 (es) |
| ZA (1) | ZA202102322B (es) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2306024C (en) | 1997-10-01 | 2011-04-26 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
| US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
| KR100334860B1 (ko) | 1998-03-12 | 2002-05-02 | 야마오카 요지로 | 규소강판 및 그 제조방법 |
| US7501113B2 (en) * | 2003-02-04 | 2009-03-10 | Philip Morris Usa Inc. | Aerosol formulations and aerosol delivery of buprenorphine |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| WO2005079761A1 (en) | 2004-02-17 | 2005-09-01 | Transoral Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| EP1715853A4 (en) * | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
| GB0423800D0 (en) | 2004-10-27 | 2004-12-01 | Orexo Ab | New pharmaceutical formulations |
| WO2006089082A2 (en) * | 2005-02-17 | 2006-08-24 | Velcera Pharmaceuticals | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| US20070123562A1 (en) * | 2005-05-25 | 2007-05-31 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the-night insomnia |
| DE102005034549A1 (de) | 2005-07-23 | 2007-02-01 | Siemens Ag | Übersetzen von MAC-Adressen |
| JP2009534387A (ja) * | 2006-04-19 | 2009-09-24 | ノヴァデル ファーマ インコーポレイテッド | 安定な含水アルコール性経口噴霧調剤物および方法 |
| EP2152247A4 (en) | 2007-05-10 | 2012-12-26 | Novadel Pharma Inc | COMPOSITIONS AND METHODS ANTI-INSOMNIA |
| US8946208B2 (en) * | 2007-08-31 | 2015-02-03 | Archimedes Development Limited | Non-aqueous pharmaceutical composition |
| US20090246256A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
| CN101780038A (zh) * | 2010-03-30 | 2010-07-21 | 上海现代药物制剂工程研究中心有限公司 | 酒石酸唑吡坦口腔喷雾剂及其制备方法 |
| RS54037B1 (sr) * | 2010-10-12 | 2015-10-30 | Ivax Pharmaceuticals Ireland | Uređaj za nazalni sprej |
-
2019
- 2019-10-04 SG SG11202103255RA patent/SG11202103255RA/en unknown
- 2019-10-04 GE GEAP201915600A patent/GEP20237492B/en unknown
- 2019-10-04 EP EP19790867.6A patent/EP3863604B1/en active Active
- 2019-10-04 US US17/283,328 patent/US12133845B2/en active Active
- 2019-10-04 JP JP2021517825A patent/JP2022501407A/ja active Pending
- 2019-10-04 WO PCT/IN2019/050734 patent/WO2020075183A1/en not_active Ceased
- 2019-10-04 AU AU2019358394A patent/AU2019358394B2/en active Active
- 2019-10-04 ES ES19790867T patent/ES2998438T3/es active Active
- 2019-10-04 KR KR1020217013424A patent/KR102860999B1/ko active Active
- 2019-10-04 IL IL282020A patent/IL282020B2/en unknown
- 2019-10-04 PE PE2021000465A patent/PE20211007A1/es unknown
- 2019-10-04 HU HUE19790867A patent/HUE069302T2/hu unknown
- 2019-10-04 PL PL19790867.6T patent/PL3863604T3/pl unknown
- 2019-10-04 EA EA202190765A patent/EA202190765A1/ru unknown
- 2019-10-04 TN TNP/2021/000051A patent/TN2021000051A1/en unknown
- 2019-10-04 JO JOP/2021/0068A patent/JOP20210068A1/ar unknown
- 2019-10-04 MA MA53050A patent/MA53050B1/fr unknown
- 2019-10-04 CN CN201980074223.3A patent/CN112996488B/zh active Active
- 2019-10-04 BR BR112021006551A patent/BR112021006551A2/pt unknown
- 2019-10-04 CA CA3115195A patent/CA3115195A1/en active Pending
- 2019-10-04 MX MX2021003975A patent/MX2021003975A/es unknown
- 2019-10-07 UY UY0001038405A patent/UY38405A/es unknown
- 2019-10-08 AR ARP190102862A patent/AR116721A1/es unknown
-
2021
- 2021-04-05 PH PH12021550748A patent/PH12021550748A1/en unknown
- 2021-04-06 CL CL2021000856A patent/CL2021000856A1/es unknown
- 2021-04-08 EC ECSENADI202124213A patent/ECSP21024213A/es unknown
- 2021-04-08 ZA ZA2021/02322A patent/ZA202102322B/en unknown
- 2021-04-08 DO DO2021000060A patent/DOP2021000060A/es unknown
- 2021-05-06 CO CONC2021/0005969A patent/CO2021005969A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005326A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| RU2011119988A (ru) | Композиции инсулинов длительного действия | |
| PE20171345A1 (es) | Modificador del sabor dulce | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| CY1117995T1 (el) | Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις | |
| MX2020002191A (es) | Agentes antivirales contra la hepatitis b. | |
| MX2018011102A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX384378B (es) | Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca. | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| JOP20190086A1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| AR067491A1 (es) | Preparacion recubierta | |
| UY31775A (es) | Compuestos heterocíclicos como inhibidores de mek | |
| CY1106055T1 (el) | Τυποποιηση των υποκατεστημενων βενζιμιδαζολων | |
| UY36546A (es) | “ciclopropabenzofuranil-piridopirazindionas novedosas”. | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| UY38405A (es) | Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos | |
| MX2012003446A (es) | Gotas oculares. | |
| EA201791191A1 (ru) | Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол | |
| PE20091209A1 (es) | Sales de propionato de 3-(2,2,2-trimetilhidrazinio) | |
| AR079032A1 (es) | Preparacion de un concentrado del factor h | |
| CL2025001013A1 (es) | Solución líquida de buen sabor con alta concentración de miglustat. | |
| AR130899A1 (es) | Desecante y herbicida no selectivo | |
| RU2015105452A (ru) | Препарат для лечения костных наростов, головных болей и болей в сердце | |
| CY1124264T1 (el) | Απο toy στοματος θεραπευτικος παραγοντας του θυρεοειδους |